ArticleIntractable & rare diseases research2024

Evaluation of the safety and efficacy of miglustat for the treatment of Chinese patients with Niemann-Pick disease type C: A prospective, open-label, single-arm, phase IV trial.

Huiwen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.